Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Genet. 2015 Oct;47(10):1168-78. doi: 10.1038/ng.3398. Epub 2015 Sep 7.

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

Author information

1
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
2
University of North Carolina-Rex Healthcare, Chapel Hill, North Carolina, USA.
3
Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
4
Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.
5
Department of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.
6
Eppley Cancer Institute, University of Nebraska, Lincoln, Nebraska, USA.
7
Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
8
Department of Surgery, Feinberg School of Medicine Northwestern University, Chicago, Illinois, USA.
9
Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine Northwestern University, Chicago, Illinois, USA.
10
Department of Surgery, NorthShore University HealthSystem, Evanston, Illinois, USA.
11
Department of Pathology, David Rubenstein Center for Pancreatic Cancer Research, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult. Here we have overcome this problem by applying blind source separation to a diverse collection of PDAC gene expression microarray data, including data from primary tumor, metastatic and normal samples. By digitally separating tumor, stromal and normal gene expression, we have identified and validated two tumor subtypes, including a 'basal-like' subtype that has worse outcome and is molecularly similar to basal tumors in bladder and breast cancers. Furthermore, we define 'normal' and 'activated' stromal subtypes, which are independently prognostic. Our results provide new insights into the molecular composition of PDAC, which may be used to tailor therapies or provide decision support in a clinical setting where the choice and timing of therapies are critical.

PMID:
26343385
PMCID:
PMC4912058
DOI:
10.1038/ng.3398
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center